Results 21 to 30 of about 13,127 (167)

Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: in vitro characterization, stability, in vitro cytotoxicity, and antiviral activity using real time cell analysis

Drug Delivery, 2022
Favipiravir, an RNA-dependent RNA polymerase (RdRp) inhibitor, is used to treat patients infected with influenza virus and most recently with SARS-CoV-2.
Ayca Yildiz Pekoz, Ozlem Akbal Dagistan, Hanan Fael, Meltem Culha, Aybige Erturk, Nur Sena Basarir, Gokben Sahin, Muge Serhatli, Gamze Cakirca, Saban Tekin, Leyla Semiha Sen, Mustafa Sevim, Lutfiye Mulazimoglu Durmusoglu, Berrak C. Yegen   +13 more
doaj   +1 more source

Novel favipiravir pattern-based learning model for automated detection of specific language impairment disorder using vowels

, 2022
Specific language impairment (SLI) is one of the most common diseases in children, and early diagnosis can help to obtain better timely therapy economically.
Barua, Prabal Datta, Fujita, Hamido, Aydemir, Emrah, Kaysi, Feyzi, Tuncer, Turker, Acharya, U. Rajendra, Acharya, U Rajendra, Palmer, Elizabeth, Dogan, Sengul, Erten, Mehmet   +9 more
core   +1 more source

Effects of favipiravir and hydroxycloroquine on fracture healing in rats [PDF]

, 2022
Amaç: Kırık iyileşmesi ya da kırığın kaynamaması, pek çok faktörün bir arada etkileşimde bulunduğu bir süreci ifade eder. Bu sürecin değişik basamaklarına etki eden birçok tedavi, fiziksel ve biyolojik terapi yöntemleri olduğu gibi kırığın kaynamamasına ...
Tekçe, Giray
core   +2 more sources

Cost-effectiveness of Favipiravir in moderately to severely ill COVID-19 patients in the real-world setting of Saudi arabian pandemic referral hospitals

Saudi Pharmaceutical Journal, 2023
Purpose: We aimed to evaluate the cost effectiveness of Favipiravir treatment versus standard of care (SC) in moderately to severely ill COVID-19 patients from the Saudi healthcare payer perspective.
Ahmad Alamer, Abdulaali R. Almutairi, Shiraz Halloush, Ahmed Al-jedai, Ahmed Alrashed, Mashael AlFaifi, Yahya Mohzari, Malak Almutairi, Fatimah AlHassar, Jude Howaidi, Wedad Almutairi, Ivo Abraham, Nimer Alkhatib   +12 more
doaj   +1 more source

Small Molecule Inhibition of Mononegavirales RNA Polymerases. [PDF]

J Med Virol
ABSTRACT The order Mononegavirales includes several non‐segmented negative‐sense RNA viruses that are significant human pathogens, whose transcription and replication depend on multifunctional RNA‐dependent RNA polymerase (L protein). Recent discoveries in cryo‐electron microscopy (cryo‐EM) have elucidated the structures of these polymerases and their ...
Cao CR, Mohammed M, Yang G, Wang D.
europepmc   +2 more sources

Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19.

PLoS Medicine, 2022
BackgroundEarly antiviral treatment is effective for Coronavirus Disease 2019 (COVID-19) but currently available agents are expensive. Favipiravir is routinely used in many countries, but efficacy is unproven.
David M Lowe, Li-An K Brown, Kashfia Chowdhury, Stephanie Davey, Philip Yee, Felicia Ikeji, Amalia Ndoutoumou, Divya Shah, Alexander Lennon, Abhulya Rai, Akosua A Agyeman, Anna Checkley, Nicola Longley, Hakim-Moulay Dehbi, Nick Freemantle, Judith Breuer, Judith Breuer, Joseph F Standing, FLARE Investigators   +18 more
doaj   +1 more source

A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test

International Journal of Infectious Diseases, 2021
As of October 2020, there is still no specific drug to treat COVID-19 as it rages worldwide. Favipiravir, indicated for the treatment of new and re-emerging influenza infections, has been suggested to be effective against SARS-CoV-2, although this is not
Yushi Murai, Hitoshi Kawasuji, Yusuke Takegoshi, Makito Kaneda, Kou Kimoto, Akitoshi Ueno, Yuki Miyajima, Koyomi Kawago, Yasutaka Fukui, Chika Ogami, Ippei Sakamaki, Yasuhiro Tsuji, Yoshitomo Morinaga, Yoshihiro Yamamoto   +13 more
doaj   +1 more source

Quantitative analysis of two COVID-19 antiviral agents, favipiravir and remdesivir, in spiked human plasma using spectrophotometric methods; greenness evaluation

BMC Chemistry, 2023
Favipiravir and remdesivir have been included in the COVID-19 treatment guidelines panel of several countries. The main objective of the current work is to develop the first validated green spectrophotometric methods for the determination of favipiravir ...
Afnan S. Batubara, Ahmed H. Abdelazim, Ahmed A. Almrasy, Mohammed Gamal, Sherif Ramzy   +4 more
doaj   +1 more source

Determination of Favipiravir in Human Blood Plasma by HPLC-MS/MS

Разработка и регистрация лекарственных средств, 2023
Introduction. Favipiravir is one of the most well-known broad-spectrum drugs against many RNA viruses, including the severe acute respiratory syndrome virus 2 [severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)].
T. N. Komarov, P. A. Karpova, O. A. Archakova, D. S. Shchelgacheva, P. K. Karnakova, N. S. Bagaeva, K. Ya. Zaslavskaya, P. A. Bely, I. E. Shohin   +8 more
doaj   +1 more source

Chandipura Virus: An Emerging Neurological Threat Transmitted by Sandflies in India. [PDF]

Immun Inflamm Dis
Chandipura virus (CHPV), a neurotropic arbovirus transmitted primarily by sandflies, has emerged as a significant public health concern in India following recurrent outbreaks with high pediatric fatality rates. This review highlights the virus's virology, transmission dynamics, clinical features, and the urgent need for improved diagnostics ...
Zargar AA, Gupta R, Krishnamoorthy P.
europepmc   +2 more sources